ClinicalTrials.gg
CompletedNCT07059533TrainStimUpdated Jul 10, 2025

Training in Combination With Non-invasive Brain Stimulation

An interventional study of Verum and Placebo in Motor Skill Acquisition in Healthy Older Adults, sponsored by Friedhelm Hummel. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Friedhelm Hummel · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 8 years 3 months after the study started (first participant enrolled Mar 2017, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to investigate the impact of non-invasive brain stimulation on motor skill acquisition in healthy individuals. Participants performed a motor task with non-invasive brain stimulation applied over the area of the brain where movements were controlled. The study compared motor skill performance between with the active stimulation and the placebo stimulation.

Read the detailed description

This study implemented a randomized, double-blinded, and sham-controlled design, investigating the effects of non-invasive brain stimulation on motor skill acquisition in healthy individuals.

02

Conditions studied

  • Motor Skill Acquisition in Healthy Older Adults

Keywords

  • Non-invasive brain stimulation
  • Transcranial direct current stimulation
03

In context

Lead sponsor

Friedhelm Hummel is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age equals to or over 18 years old
  • absence of major neurological, psychiatric and physical impairment, with normal or corrected to normal vision
  • right handed
  • in good general health

Exclusion criteria

Exclusion Criteria:

  • professional musicians/stenotypist
  • unable to consent
  • unable to perform the task as required (instructions and setup)
  • exclusion criteria for magnetic resonance imaging (MRI), transcranial electrical stimulation (tES), transcranial magnetic stimulation (TMS)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Verum

    anodal transcranial direct current stimulation

    Other: Verum

  • Placebo comparator
    Placebo

    40 seconds of stimulation delivered at the beginning of training (with 8 seconds ramp-up and 5 seconds ramp-down times)

    Other: Placebo

Interventions

  • OtherVerum

    anodal transcranial direct current stimulation: 20 minutes of stimulation with 1 mA (ramp-up/ramp-down times of 8 seconds)

  • OtherPlacebo

    anodal transcranial direct current stimulation with 40 seconds of stimulation delivered at the beginning of training (with 8 seconds ramp-up and 5 seconds ramp-down times)

06

What researchers measure

Primary outcomes

  1. Motor performance

    Replication of a nine-digit sequence displayed on a screen, as quickly and as accurately as possible, using the left hand

    Time frame: From the start of the practice to the end of training at 5 days (and follow up on the 10th day and 60th day)

07

Study locations

1 site
  • Campus Biotech
    Geneva, Canton of Geneva 1202, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jan 2025, 94 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Mar 31, 2017
Primary completionActual
Jan 31, 2025
CompletionActual
Jan 31, 2025
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07059533
Lead sponsor
Friedhelm Hummel
Responsible party
Friedhelm Hummel (Full professor, Ecole Polytechnique Fédérale de Lausanne) — Sponsor-investigator
First posted
Jul 10, 2025
Start date
Mar 31, 2017
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025
Last update
Jul 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion